


1 Supplementary material to “Effectiveness and Safety of Baidu Jieduan Granules for COVID-19: A Retrospective Observational Multicenter Study” written by
2 XU Xiang-ru, ZHANG Wen, WU Xin-xin, et al published in Chinese Journal of Integrative Medicine (DOI: <https://doi.org/10.1007/s11655-022-3673-x>)



Appendix 1. Flow diagram

3

4

5

6 **Appendix 2. Primary and Secondary Clinical Outcomes in the population stratified by age**

	Mild group (n = 92)			Moderate group (n = 138)		
	< 60 y (n = 73)	≥ 60 y (n = 19)	<i>P</i> vaule	< 60 y (n = 79)	≥ 60 y (n = 59)	<i>P</i> vaule
Primary clinical outcome						
Day 28 disease progression rate, no. (%)	0	0	-	5 (6.3%)	5 (8.5%)	0.744
Day 28 discharge rate, no. (%)	73 (100%)	19 (100%)	-	74 (93.7%)	54 (91.5%)	0.744
Secondary clinical outcome						
Negative conversion time of nucleic acid, median (IQR), d	10 (3, 15)	3 (2, 9)	0.001*	15 (11.75, 19.25)	10 (4, 16)	0.002#
Duration of hospital stay, median (IQR), d	13 (10, 17.5)	12 (10, 14)	0.36	18.5 (14, 23)	17.5 (14, 24.25)	0.722
Number of fever reduction cases (%)	42 (100%)	8 (100%)	-	63 (94.0%)	28 (87.5%)	0.265
Fever reduction time, median (IQR), d	4 (2, 5)	5 (3, 6)	0.309	4 (3, 6)	3 (2, 6)	0.046
Number of cough reduction cases (%)	48 (92.3%)	12 (92.3%)	-	58 (89.2%)	34 (89.5%)	0.969
Cough reduction time, median (IQR), d	7.5 (5, 10)	6 (2.25, 9)	0.203	10 (6.75, 14)	8 (5, 11.25)	0.088
Number of fatigue reduction cases (%)	26 (100%)	7 (100%)	-	51 (92.7%)	31 (88.6%)	0.499
Fatigue reduction time, median (IQR), d	5 (3, 8)	6 (2, 9)	0.983	10 (6, 12)	9 (6, 12)	0.989

7 Abbreviations: IQR, interquartile range; *: < 60 y vs ≥ 60 y in mild group, *P* < 0.005; #: < 60 y vs ≥ 60 y in moderate group, *P* < 0.005.

Appendix 3. Patients' Clinical Status on days 7, 14, and 28

	Total (n = 230)	Mild group (n = 92)	Moderate group (n = 138)
Time to clinical improvement, d	12 (10, 17)	12 (10, 16)	12 (9, 17.25)
Clinical improvement rate, No. (%)			
Day 7	22 (9.6%)	7 (7.6%)	15 (10.9%)
Day 14	155 (67.4%)	63 (68.5%)	92 (66.7%)
Day 28	220 (95.7%)	92 (100%)	128 (92.8%)
Six-category scale at day 7, No. (%)			
1- discharge	7/230 (3%)	7/92 (7.6%)	0/138
2- mild	100/230 (43.5%)	85/92 (92.4%)	15/138 (10.9%)
3- moderate	109/230 (47.4%)	0/92	109/138 (47.4%)
4- severe	12/230 (5.2%)	0/92	12/138 (8.7%)
5-critical	2/230 (0.9%)	0/92	2/138 (1.4%)
Six-category scale at day 14, No. (%)			
1- discharge	103/225 (45.8%)	63/92 (68.5%)	40/133 (30.1%)
2- mild	82/225 (36.4%)	29/92 (31.5%)	53/133 (39.8%)
3- moderate	34/225 (15.1%)	0/92	34/133 (25.6%)
4- severe	3/225 (1.3%)	0/92	3/133 (2.3%)
5- critical	1/225 (0.4%)	0/92	1/133 (0.4%)
Six-category scale at day28, No. (%)			
1- discharge	213/222 (95.9%)	92/92 (100%)	121/130 (93.1%)
2- mild	7/222 (3.2%)	0/92	7/130 (5.4%)
3- moderate	1/222 (0.5%)	0/92	1/130 (0.8%)
5- critical	1/222 (0.5%)	0/92	1/130 (0.8%)

Appendix 4. Infection indicators at baseline, days 3, 7, and 14

	Baseline	Day3	Day7	Day14
Hematologic				
WBC, median (IQR), ×10⁹/L				
All patients	4.6 (3.61,5.99)	4.4 (3.25,5.49)	5.36 (4.38,6.79)	5.39 (4.43,6.58)
Mild group	5.02 (3.86,6.12)	4.5 (3.16,5.02)	5.29 (4.36,6.24)	5.27 (4.47,6.2)
Moderate group	4.42 (3.55,5.68)	4.4 (3.31,5.8)	5.41 (4.38,6.96)	5.41 (4.42,6.79)
NC (× 10⁹/L)				
All patients	2.66 (2.09,3.58)	2.64 (1.96,3.58)	3.26 (2.23,4.36)	3.18 (2.37,4.18)
Mild group	2.79 (2.22,3.72)	2.47 (1.86,3.21)	2.98 (2.2,3.94)	3.09 (2.19,3.77)
Moderate group	2.58 (1.95,3.54)	2.77 (2.05,4.34)	3.37 (2.3,5.11)	3.25 (2.38,4.5)
LYM, median (IQR), ×10⁹/L				
All patients	1.2 (0.84,1.64)	1.04 (0.74,1.35)	1.37 (0.93,1.81)	1.47 (1.16,1.86)
Mild group	1.41 (1.03,1.85)	1.14 (0.89,1.59)	1.61 (1.16,1.99)	1.67 (1.19,2)
Moderate group	1.14 (0.8,1.55)	0.93 (0.68,1.31)	1.25 (0.87,1.62)	1.42 (1.13,1.71)
PLT, median (IQR), ×10⁹/L				
All patients	174 (134,236)	186 (139.5,233.5)	246 (193,317)	246 (196,289.75)
Mild group	181 (151,243)	197.5 (148,228.75)	246 (197,311)	249 (191,295)
Moderate group	160 (129,224.25)	184 (137.5,240.5)	244 (191.25,321)	246 (197,287.5)
Infection-related indices				
CRP (mg/L)				
All patients	8.15 (1.3,23.07)	16.72 (7.73,27.24)	2.29 (0.61,8.71)	1.4 (0.59,3.32)
Mild group	2.69 (0.5,12.97)	8.3 (2.3,15.3)	0.86 (0.5,3.67)	0.85 (0.4,2.8)
Moderate group	13.56 (3.16,35.24)	21.6 (8.66,31.13)	4.61 (1.42,15.55)	1.59 (0.7,3.94)

PCT, median (IQR), ng/mL

All patients	0.08 (0.04,0.11)	0.07 (0.05,0.11)	0.06 (0.03,0.1)	0.05 (0.03,0.07)
Mild group	0.05 (0.03,0.09)	0.05 (0.04,0.07)	0.06 (0.03,0.08)	0.05 (0.03,0.07)
Moderate group	0.08 (0.05,0.12)	0.08 (0.06,0.15)	0.07 (0.03,0.1)	0.06 (0.03,0.08)

ESR, median (IQR), mm/h

All patients	35.5 (13,66.25)	60 (34.75,102.5)	35 (14,81)	36.5 (22.25,76.5)
Mild group	25 (9,62)	39 (30,67)	27 (12,71.5)	50 (25,92)
Moderate group	51 (26,72)	82 (47,125)	51 (20.75,84.5)	35 (20.25,63.75)

Abbreviations: IQR, interquartile range; WBC, white blood cell; NC, neutrophil count; LYM, lymphocyte counts; PLT, platelet counts; CRP, C-reactive protein; PCT, procalcitonin; ESR, erythrocyte sedimentation rat